Hansa Biopharma (HNSA) Jefferies Global Healthcare Conference 2026 summary

Company overview and platform

• Developed a novel IgG degrader platform targeting rapid reduction of IgG for highly sensitized kidney transplant and gene therapy patients.

• Pipeline includes a second enzyme targeting Guillain-Barré syndrome.

Market opportunity and unmet need

• Around 100,000 patients are on the U.S. kidney wait list, with 15% highly sensitized and facing low chances of finding a match.

• Estimated market opportunity for imlifidase exceeds $1 billion due to lack of approved alternatives.

Clinical data and regulatory milestones

• Positive phase III top-line data; detailed results to be presented at ATC, including secondary endpoints and safety.

• BLA submitted; PDUFA date set for December 19th, with a typical FDA review process underway.

• Post-marketing commitments and label scope to be discussed later in the year.